Dunvegan Associates’s Novartis NVS Stock Holding History

Dunvegan Associates’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	$3.15M	Sell	40,876 -374	-0.9%	-$29.7K	3.7%	8
2015 Q3	$3.4M	Sell	41,250 -507	-1%	-$45.1K	3.87%	7
2015 Q2	$3.68M	Sell	41,757 -7,761	-16%	-$712K	4.07%	7
2015 Q1	$4.38M	Sell	49,518 -1,055	-2%	-$93.6K	3.87%	6
2014 Q4	$4.2M	Sell	50,573 -2,017	-4%	-$167K	3.65%	8
2014 Q3	$4.44M	Sell	52,590 -447	-0.8%	-$36.2K	4.01%	8
2014 Q2	$4.3M	Sell	53,037 -296	-0.6%	-$23.3K	3.6%	9
2014 Q1	$4.06M	Sell	53,333 -5,001	-9%	-$364K	3.42%	8
2013 Q4	$4.2M	Sell	58,334 -2,341	-4%	-$163K	3.47%	8
2013 Q3	$4.17M	Sell	60,675 -707	-1%	-$46.8K	3.08%	10
2013 Q2	$3.89M	Buy	+61,382	New	+$3.99M	3%	10

Other funds holding NVS

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $22.8B AUM 25.09% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Institutional Capital Chicago, Illinois $6.75B AUM 3.51% 1-Year Est. Return

Dunvegan Associates's NVS Position: Q4 2015 in Review

Dunvegan Associates reduced its Novartis (NVS) stake by 0.91% in Q4 2015, selling an estimated $29.7K and leaving 40,876 shares worth $3.15M. The position accounts for 3.7% of the portfolio, ranked #8.

Dunvegan Associates first reported a position in NVS in Q2 2013 and has held it in 11 quarters since. The position peaked at $4.44M in Q3 2014. 927 funds tracked by Wall St. Rank hold NVS as of Q4 2015.

Dunvegan Associates held 40,876 shares of Novartis worth $3.15M as of Q4 2015.
Dunvegan Associates sold 374 Novartis shares in Q4 2015, an estimated $29.7K.
Novartis made up 3.7% of Dunvegan Associates's portfolio in Q4 2015, its #8 holding.
Dunvegan Associates first reported a position in Novartis in Q2 2013 and has held it in 11 quarters since.
Dunvegan Associates's Novartis position peaked at $4.44M in Q3 2014.
927 funds tracked by Wall St. Rank held Novartis as of Q4 2015.

Based on Dunvegan Associates's 13F filing for Q4 2015, filed 28 Apr 2017.